article thumbnail

High Throughput Screening (HTS)

Sygnature Discovery

High Throughput Screening Workflow The HTS Workflow is tailored to each of our clients requirements, focusing on developing robust assays with a flexible approach, especially in selecting hits to balance false positives and negatives. The process begins with assay development or transfer.

article thumbnail

Taking a 3D view of heart failure with River BioMedics

Sygnature Discovery

This exciting partnership combines our novel assay development and hit identification expertise with River BioMedics unique, state-of-the-art technology: advanced human-predictive in vitro 3D heart models, plus their deep knowledge of cardiac biology. River BioMedics is progressing its cardiovascular disease programmes following a €1.8m

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.

article thumbnail

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

The Pharma Data

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. VANCOUVER, Jan.

FDA 52
article thumbnail

The hidden risks of over-reliance on healthy donor material

Drug Target Review

Diseased cells can respond differently to treatment, leading to unforeseen adverse events, including severe toxicity and even death. Addressing unexpected manufacturing challenges, safety concerns, or efficacy issues in later stages can significantly delay clinical development and escalate costs.

article thumbnail

Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time

Agency IQ

As for the second challenge, potential confounders present at the time of treatment initiation can be controlled for using randomization, but it may be more difficult for sponsors to detect and adjust for factors that arise after the investigational product’s administration (e.g.,

FDA 40
article thumbnail

Article EMA Thank You EMA finalizes clinical anticancer therapeutic guidance update

Agency IQ

Predictive biomarkers enable the identification and selection of patients who are more likely to benefit from a specific treatment and would achieve a better clinical outcome in response to a specific treatment. Prognostic biomarkers enable patient selection that would have a better clinical outcome irrespective of treatment.